Table 5.

Adverse events at 6 months.

Variable	SD-RTX (n=9)	LD-RTX (n=11)*	p
Death, n (%)	0	1 (9.1)	0.45
Total number of selected events, n (%)	1 (11.1)	2 (18.2)	1
Cancer, n (%)	0	0	/
Infection, n (%)	0	1 (9.1)	0.45
Liver function impairment, n (%)	0	1 (9.1)	0.45
Infusion reaction, n (%)	1 (11.1)	0	0.45

SD-RTX, standard-dose rituximab; LD-RTX, low-dose rituximab.

*Two patients lost to follow-up.